Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 14;10(10):2129.
doi: 10.3390/jcm10102129.

Fellow-Eye Comparison between Phaco-Microhook Ab-Interno Trabeculotomy and Phaco-iStent Trabecular Micro-Bypass Stent

Yuji Takayanagi  1 , Sho Ichioka  1 , Akiko Ishida  1 , Aika Tsutsui  1 , Masaki Tanito  1
Affiliations

Fellow-Eye Comparison between Phaco-Microhook Ab-Interno Trabeculotomy and Phaco-iStent Trabecular Micro-Bypass Stent

Yuji Takayanagi et al. J Clin Med. .

Abstract

The aim of this study is to compare the surgical efficacy and safety between microhook ab-interno trabeculotomy (µLOT) and iStent trabecular micro-bypass stent implantation when both were combined with cataract surgery in both eyes of patients. Sixty-four glaucomatous eyes (32 participants; mean age, 75.9 ± 7.6 years; 15 men, 17 women) were included retrospectively. Intraocular pressure (IOP), number of antiglaucoma medications, best-corrected visual acuity (BCVA), anterior chamber flare (ACF) and corneal endothelial cell density (CECD) were evaluated preoperatively, as well as 2, 3, 6, and 12 months postoperatively. Surgical complications and interventions were compared between the procedures. The preoperative IOP and medications with µLOT (18.8 ± 5.7 mmHg and 3.0 ± 1.2, respectively) were higher than with the iStent (15.5 ± 3.4 mmHg and 2.7 ± 1.2, respectively) (p = 0.0001 and p = 0.0437, respectively). At 12 months, the µLOT values (12.6 ± 2.3 mmHg and 2.3 ± 0.9, respectively) were identical to iStent (12.8 ± 2.5 mmHg and 2.3 ± 0.9, respectively) (p = 0.0934 and p = 0.3251, respectively). At 12 months, the IOP decreased more with µLOT (6.2 mmHg, 29.5%) than iStent (2.7 mmHg, 15.6%) (p = 0.0003). The decrease in medications was greater with µLOT (0.7) than iStent (0.4) (p = 0.0437). Survival rate of IOP control ≤15 mmHg and IOP reduction ≥20% was significantly higher after µLOT (40.6% at 12 months) than iStent (18.8%) (p = 0.0277). The frequency of layered hyphema was significantly greater with µLOT (8 eyes, 25%) than iStent (0 eyes, 0%) (p = 0.0048). The increase in the ACF at 2 weeks postoperatively was significantly greater with µLOT than iStent (p = 0.0156), while changes in the BCVA and CECD were identical between groups. The fellow-eye comparison showed that the IOP reduction was greater with µLOT than iStent when combined with cataract surgery.

Keywords: Tanito microhook (TMH); cataract surgery; fellow-eye comparison; iStent trabecular micro-bypass system; intraocular pressure; microhook ab-interno trabeculotomy; minimally invasive glaucoma surgery.

PubMed Disclaimer

Conflict of interest statement

The microhooks used were co-developed by Masaki Tanito, MD, PhD, and Inami & Co., Ltd. (Tokyo, Japan). Tanito receives royalties from Inami & Co., Ltd. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Other authors report no conflict of interest in this work.

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves for successful intraocular pressure (IOP) control in the iStent and microhook ab-interno trabeculotomy (µLOT) groups using two failure criteria, i.e., criterion A (a), IOP < 20% reduction from preoperative IOP value and/or >15 mmHg and criterion B (b), IOP < 20% reduction from preoperative value and/or >12 mmHg. Patients who did not satisfy the IOP failure criteria and required additional glaucoma surgery and/or who had no light perception were also classified as failures. The log-rank statistics between the two groups were 1.81 for criterion A and 4.85 for criterion B (p = 0.1780 and p = 0.0277, respectively).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Foster A., Resnikoff S. The impact of Vision 2020 on global blindness. Eye. 2005;19:1133–1135. doi: 10.1038/sj.eye.6701973. - DOI - PubMed
    1. Heijl A., Leske M.C., Bengtsson B., Hyman L., Bengtsson B., Hussein M. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002;120:1268–1279. doi: 10.1001/archopht.120.10.1268. - DOI - PubMed
    1. O’Connor J., Soon Ang G., Fan Gaskin J.C., Nguyen D.Q., Crowston J.G. Wound healing modulation in glaucoma filtration surgery—Conventional practices and new perspectives: Antivascular endothelial growth factor and novel agents (Part II) J. Curr. Glaucoma Pract. 2014;8:46–53. doi: 10.5005/jp-journals-10008-1160. - DOI - PMC - PubMed
    1. Konopińska J., Deniziak M., Saeed E., Bartczak A., Zalewska R., Mariak Z., Rękas M. Prospective randomized study comparing combined phaco-express and phacotrabeculectomy in open angle glaucoma treatment: 12-Month follow-up. J. Ophthalmol. 2015;2015:720109. doi: 10.1155/2015/720109. - DOI - PMC - PubMed
    1. Lavia C., Dallorto L., Maule M., Ceccarelli M., Fea A.M. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PLoS ONE. 2017;12:e0183142. doi: 10.1371/journal.pone.0183142. - DOI - PMC - PubMed

LinkOut - more resources

  NODES
INTERN 11
twitter 2